California Stem Cell Agency Symposium: 'Vague Fears' vs. Potential Genetic Alteration of Human Race
By David Jensen,
California Stem Cell Report
| 06. 11. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
California’s $3 billion stem cell agency has called a high-level meeting for next fall to examine a "red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
The topic is a technique that makes it much easier to alter the genetic make-up of individuals in a way that can be inherited by their offspring.
In April, scientists in China reported genetically modifying human embryos in what was regarded as a “world first.” (See
here and
here.)
More recently
Marcy Darnovsky, executive director of the
Center for Genetics and Society in Berkeley,
wrote on May 28 about how the subject was viewed at a meeting called, “Biotech and the Ethical Imagination: A Global Summit.”
“The far end of techno-enthusiastic perspectives, both on human germline modification specifically and on biotech in general, was represented by Harvard experimental psychologist and popular science writer Steven Pinker. In...
Related Articles
By Jenny Kleeman, The Guardian | 05.30.2026
On a Friday evening in late April, Cathy Tie, the Canadian serial entrepreneur and self-styled “Biotech Barbie”, is centre stage at New York City’s famous Carnegie Hall, performing Saint-Saens’ Piano Concerto No 2 on a gleaming Steinway grand piano, accompanied...
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Rebecca Roberts, The Scientist | 05.19.2026
Scientists have had prenatal gene therapy in their sights for decades; by treating the fetus in utero, they can potentially prevent the long-term damage caused by severe, early-onset genetic disorders. Despite its success in preclinical studies, the method has...
By Moe Alsumidaie, The Clinical Trial Vanguard | 05.26.2026
Picture the moment a gene therapy trial’s safety monitor pulls up a patient record — years after the last dose, long after the trial team has dissolved and the CRO contract has closed — and finds a tumor. The vector...